Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Arf-GAP with GTPase, ankyrin repeat, and PH domain-containing protein 3 (AGAP3) is a multi-domain synaptic signaling protein. It is a component of the NMDA receptor complex, where it functions as a GTPase-activating protein (GAP) for Arf6 and possesses a GTPase-like domain. AGAP3 links NMDA receptor activation to trafficking of AMPA-type glutamate receptors during long-term potentiation (LTP), a fundamental mechanism of synaptic plasticity and memory. AGAP3 contains an N-terminal GTPase-like domain, a pleckstrin homology (PH) domain that mediates protein or membrane interactions, an ArfGAP domain involved in GTPase activation of ADP-ribosylation factors, and C-terminal ankyrin repeats. AGAP3 regulates Ras/ERK and Arf6 signaling cascades and is essential for proper AMPA receptor surface expression and synaptic function. Its dysregulation may impact memory consolidation and cognitive plasticity, but it is not currently an established direct therapeutic target[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arf-GAP with GTPase, ankyrin repeat, and PH domain-containing protein 3 (AGAP3).